JP2002524420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524420A5 JP2002524420A5 JP2000568509A JP2000568509A JP2002524420A5 JP 2002524420 A5 JP2002524420 A5 JP 2002524420A5 JP 2000568509 A JP2000568509 A JP 2000568509A JP 2000568509 A JP2000568509 A JP 2000568509A JP 2002524420 A5 JP2002524420 A5 JP 2002524420A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- unit dose
- fgf
- mutein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 26
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 26
- 239000012634 fragment Substances 0.000 description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 17
- 230000002491 angiogenic effect Effects 0.000 description 13
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14574398P | 1998-09-03 | 1998-09-03 | |
| US60/145,743 | 1998-09-03 | ||
| US10410398P | 1998-10-13 | 1998-10-13 | |
| US10410298P | 1998-10-13 | 1998-10-13 | |
| US60/104,102 | 1998-10-13 | ||
| US60/104,103 | 1998-10-13 | ||
| PCT/US1999/019770 WO2000013701A2 (en) | 1998-09-03 | 1999-08-27 | Angiogenically effective unit dose of fgf-2 and method of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010089915A Division JP2010163457A (ja) | 1998-09-03 | 2010-04-08 | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002524420A JP2002524420A (ja) | 2002-08-06 |
| JP2002524420A5 true JP2002524420A5 (https=) | 2006-09-14 |
| JP5329729B2 JP5329729B2 (ja) | 2013-10-30 |
Family
ID=27379656
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000568509A Expired - Lifetime JP5329729B2 (ja) | 1998-09-03 | 1999-08-27 | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 |
| JP2010089915A Pending JP2010163457A (ja) | 1998-09-03 | 2010-04-08 | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010089915A Pending JP2010163457A (ja) | 1998-09-03 | 2010-04-08 | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP2123292B1 (https=) |
| JP (2) | JP5329729B2 (https=) |
| AT (2) | ATE279937T1 (https=) |
| AU (1) | AU6022399A (https=) |
| DE (2) | DE69921348T2 (https=) |
| ES (2) | ES2233101T3 (https=) |
| WO (1) | WO2000013701A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8618052B2 (en) | 1998-10-13 | 2013-12-31 | Novartis Vaccines And Diagnostics, Inc. | Method of treating coronary artery disease by administering FGF-5 |
| US20020072489A1 (en) * | 1998-10-13 | 2002-06-13 | Whitehouse Martha J. | Angiogenically effective unit dose of FGF-2 and method of use |
| JP2002527401A (ja) | 1998-10-13 | 2002-08-27 | カイロン コーポレイション | Ｆｇｆの脈管形成的に有効な単位用量および投与方法 |
| JP5704780B2 (ja) * | 1999-08-13 | 2015-04-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 脈管形成因子の用量および心筋血流を改善するための投与方法 |
| US20020032153A1 (en) * | 2000-03-10 | 2002-03-14 | Whitehouse Martha Jo | Methods and compositions for the treatment and prevention of erectile dysfunction |
| EP1894570A3 (en) * | 2000-06-22 | 2009-11-11 | Novartis Vaccines and Diagnostics, Inc. | Methods and compositions for the treatment of peripheral artery disease |
| US20020115603A1 (en) | 2000-06-22 | 2002-08-22 | Chiron Corporation | Methods and compositions for the treatment of peripheral artery disease |
| KR101413844B1 (ko) | 2008-12-09 | 2014-06-30 | 화이자 백신스 엘엘씨 | ＩｇＥ ＣＨ３ 펩티드 백신 |
| WO2018200040A1 (en) * | 2017-04-26 | 2018-11-01 | University Of Cincinnati | Compositions of fibroblast growth factor ligands and methods of treating patients unergoing ischemia-reperfusion therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956455A (en) | 1984-03-05 | 1990-09-11 | The Salk Institute For Biological Studies | Bovine fibroblast growth factor |
| US5155214A (en) | 1984-03-05 | 1992-10-13 | The Salk Institute For Biological Studies | Basic fibroblast growth factor |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5439818A (en) | 1985-09-12 | 1995-08-08 | Scios Nova Inc. | DNA encoding human recombinant basic fibroblast growth factor |
| ATE105868T1 (de) * | 1985-09-12 | 1994-06-15 | Scios Nova Inc | Rekombinanter fibroblast-wachstumsfaktor. |
| US5852177A (en) * | 1987-02-24 | 1998-12-22 | Takeda Chemical Industries, Ltd. | Basic fibroblast growth factor (bFGF) muteins |
-
1999
- 1999-08-27 ES ES99968630T patent/ES2233101T3/es not_active Expired - Lifetime
- 1999-08-27 AT AT99968630T patent/ATE279937T1/de not_active IP Right Cessation
- 1999-08-27 AU AU60223/99A patent/AU6022399A/en not_active Abandoned
- 1999-08-27 WO PCT/US1999/019770 patent/WO2000013701A2/en not_active Ceased
- 1999-08-27 DE DE69921348T patent/DE69921348T2/de not_active Expired - Lifetime
- 1999-08-27 JP JP2000568509A patent/JP5329729B2/ja not_active Expired - Lifetime
- 1999-08-27 ES ES04018831T patent/ES2327839T3/es not_active Expired - Lifetime
- 1999-08-27 EP EP09161208.5A patent/EP2123292B1/en not_active Expired - Lifetime
- 1999-08-27 DE DE69941034T patent/DE69941034D1/de not_active Expired - Lifetime
- 1999-08-27 AT AT04018831T patent/ATE434440T1/de not_active IP Right Cessation
- 1999-08-27 EP EP99968630A patent/EP1121142B1/en not_active Expired - Lifetime
-
2010
- 2010-04-08 JP JP2010089915A patent/JP2010163457A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002527401A5 (https=) | ||
| WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
| WO2001013031A3 (en) | Dose of an angiogenic factor and method of administering to improve myocardial blood flow | |
| WO2002022163A1 (en) | Remedies for ischemic diseases | |
| Eron et al. | Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon. | |
| JP2002524420A5 (https=) | ||
| JP2002530353A5 (https=) | ||
| WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
| WO2000013701A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
| JPH11246433A (ja) | 心筋梗塞治療剤 | |
| Nathan et al. | Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent | |
| WO1990004977A3 (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| Levy et al. | Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing | |
| Reisin et al. | More rapid relief of pain with isosorbide dinitrate oral spray than with sublingual tablets in elderly patients with angina pectoris | |
| WO1995009625A1 (en) | Use of amiodarone for the treatment of heart failure | |
| Heisel et al. | Facilitating influence of procainamide on conversion of atrial flutter by rapid atrial pacing | |
| JP2002529515A5 (https=) | ||
| US4150119A (en) | Method for treatment of vascular disease | |
| Katz et al. | Thrombolytic therapy for acute myocardial infarction in a 110-year-old man | |
| Gurbel et al. | Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty | |
| Weston et al. | Pre-hospital cardiac arrest associated with coronary artery spasm | |
| WO2000043014A8 (en) | Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections | |
| Critelli et al. | Transvenous catheter ablation of the His bundle in ventricular tachycardia | |
| Somberg et al. | Antiarrhythmic action of bethanidine | |
| JANUARY et al. | Paroxysmal ventricular tachycardia treated with intravenous injections of quinidine |